Home > Oncology > ASCO 2022 > SHINE: novel first-line treatment option for MCL

SHINE: novel first-line treatment option for MCL

Presented By
Dr Michael Wang, Anderson Cancer Center, TX, USA
Conference
ASCO 2022
Trial
Phase 3, SHINE
Bendamustine-Rituximab chemotherapy plus ibrutinib outperformed Bendamustine-Rituximab alone as a first-line treatment for older patients with mantle cell lymphoma (MCL). The phase 3 SHINE trial demonstrated a meaningful benefit of the combination therapy over the monotherapy in terms of progression-free survival (PFS) but not in overall survival (OS). Nonetheless, Bendamustine-Rituximab plus ibrutinib displayed itself as a highly effective option for the MCL population. Bendamustine-Rituximab has become the most commonly used first-line regimen for older patients with MCL [1]. The bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has transformed the care of patients with relapsed/refractory MCL [2]. Dr Michael Wang (Anderson Cancer Center, TX, USA) presented results from the phase 3 SHINE trial (NCT01776840) that randomised 523 older patients (≥65 years) with unt...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on